Long‐term safety and efficacy of long‐acting risperidone in elderly psychotic patients

This subgroup analysis of the 6‐month, open‐label Switch to Risperidone Microspheres (StoRMi) trial evaluated long‐term safety and efficacy of a direct conversion to risperidone long‐acting injectable (RLAI) in 52 elderly patients (≥65 years) with psychosis stabilized on oral or depot antipsychotic. Study outcomes included adverse events, movement disorder severity, psychiatric symptoms, functional ability, quality of life and patient...